Martin Kurian, Vivek Nimgaonkar, Omar Elghawy, Ronac Mamtani. "Real-world enfortumab vedotin +/- pembrolizumab (EV+/-P)–based treatment toxicity, treatment discontinuation, and associations with survival in advanced urothelial carcinoma (aUC).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.4562